{"url_path":"/sec/cik-0001119643/10-k/2026/item-9b","section_key":"item-9b","section_title":"Item 9B Other Information**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1119643/0001493152-26-024641-index.html","accession_number":"0001493152-26-024641","cik":"0001119643","ticker":null,"issuer_name":"NUTRA PHARMA CORP","edgar_url":"https://www.sec.gov/Archives/edgar/data/1119643/0001493152-26-024641-index.html","primary_entity_key":"0001119643","primary_entity_name":"NUTRA PHARMA CORP"},"word_count":55,"has_tables":true,"body_markdown":"**Item\n9B. Other Information**\n\n \n\nIn\nconjunction with Item 9A above (Evaluation of Internal Controls over Financial Reporting) and following our management’s assessment\nand conclusion that our internal control over financial reporting as of December 31, 2025 is ineffective, because of the material weaknesses\ndescribed above, we are seeking a new Chief Financial Officer pending funding.None"}